MLAB vs PAR
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MLAB exhibits a stable financial health profile with a Piotroski F-Score of 6/9, but it is fundamentally disconnected from its valuation. The stock trades at a massive premium to its Graham Number ($22.23) and Intrinsic Value ($4.55), with a trailing P/E of 150.54. While the forward P/E of 18.15 suggests an expected earnings recovery, the current dividend payout ratio of 98.46% is unsustainable. Long-term price performance is severely negative, indicating a persistent lack of value creation over a 5-year horizon.
PAR Technology exhibits severe financial fragility, highlighted by a critical Piotroski F-Score of 1/9, indicating poor operational health. Despite a recent transition toward positive quarterly EPS and a low Price-to-Book ratio (0.66), the stock is in a catastrophic technical downtrend, losing 77% of its value over the last year. Bearish insider activity from the CEO and CFO, combined with a history of negative profit margins, outweighs the optimistic analyst target price of $35.00.
Compare Another Pair
Related Comparisons
MLAB vs PAR: Head-to-Head Comparison
This page compares Mesa Laboratories, Inc. (MLAB) and PAR Technology Corporation (PAR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.